Cystic Fibrosis Therapeutics Market Research, Analysis, Segmentation, Trends, Size And Forecasts, Competitive Analysis, SWOT Analysis

Cystic Fibrosis Therapeutics Market Introduction

The cystic fibrosis therapeutics market is expected to experience significant growth in the coming years due to several factors, including the increasing prevalence of the disease, advancements in technology, and the development of new therapies.

One of the key drivers of the cystic fibrosis therapeutics market is the increasing prevalence of cystic fibrosis. According to the Cystic Fibrosis Foundation, approximately 30,000 people in the United States and 70,000 people worldwide are living with cystic fibrosis. As awareness of the disease increases, more patients are being diagnosed, leading to increased demand for cystic fibrosis therapeutics.

Advancements in technology and the development of new therapies are also driving market growth. In recent years, there has been a significant increase in the number of therapies available for the treatment of cystic fibrosis. These therapies include antibiotics, mucolytics, bronchodilators, pancreatic enzyme replacements, and modulators. The development of new therapies, particularly modulators, has been a major breakthrough in the management of cystic fibrosis. These therapies have the potential to address the underlying cause of the disease, rather than just the symptoms.

Despite these growth drivers, there are several challenges that may limit the growth of the cystic fibrosis therapeutics market. One of the major challenges is the high cost of treatment. Many of the therapies used for the management of cystic fibrosis are expensive, making them inaccessible to some patients. Additionally, regulatory challenges may limit the development and approval of new therapies, which may slow down market growth.

Major players in the cystic fibrosis therapeutics market include Vertex Pharmaceuticals, AbbVie Inc., Genentech, Inc., Gilead Sciences, Inc., and Mylan N.V. These companies invest heavily in research and development to develop innovative therapies for the management of cystic fibrosis. As the market continues to grow, competition among these players is expected to intensify.

Cystic Fibrosis Therapeutics Market Industry Analysis

The cystic fibrosis therapeutics market is a highly specialized and competitive industry that is driven by innovation and new product development. The industry is characterized by a small number of players who dominate the market, with the top five companies accounting for a significant share of the market.

The market is segmented based on type of therapy, including antibiotics, mucolytics, bronchodilators, pancreatic enzyme replacements, and modulators. Modulators are expected to witness the highest growth in the coming years due to their ability to target the underlying genetic mutations that cause cystic fibrosis.

The high cost of therapy is a major challenge facing the industry. The cost of treatment for cystic fibrosis can be prohibitively expensive, which limits patient access to therapy. However, with the introduction of new therapies and the growing demand for treatments, manufacturers are under increasing pressure to offer more affordable options.

The industry is highly regulated, and obtaining regulatory approval for new therapies can be a complex and time-consuming process. The regulatory environment can impact the pace of innovation and new product development, which can limit market growth.

The industry is dominated by a few key players, including Vertex Pharmaceuticals, AbbVie Inc., Genentech, Inc., Gilead Sciences, Inc., and Mylan N.V. These companies invest heavily in research and development to develop new therapies for the management of cystic fibrosis. They also focus on developing strategic partnerships and collaborations to expand their product offerings and reach a broader patient population.

Overall, the cystic fibrosis therapeutics market is expected to experience significant growth in the coming years due to the increasing prevalence of the disease, advancements in technology, and the development of new therapies. However, the high cost of therapy and regulatory challenges may hinder market growth.

Cystic Fibrosis Therapeutics Market Trends

The cystic fibrosis therapeutics market is undergoing several notable trends that are shaping the industry’s direction and future. Here are some of the major trends:

Increased use of modulators: Modulators are a class of drugs that can target the underlying genetic mutations that cause cystic fibrosis. They represent a major breakthrough in the treatment of the disease and are expected to drive the market’s growth in the coming years.
Development of personalized therapies: As our understanding of cystic fibrosis deepens, there is an increasing emphasis on developing personalized therapies that can target specific genetic mutations. This trend is expected to accelerate with advances in genetic sequencing and other technologies.
Growing emphasis on patient engagement: Patient engagement and involvement in the management of cystic fibrosis are becoming increasingly important. Patients and caregivers are demanding greater participation in decision-making, and companies are responding by developing tools and resources to help patients manage their condition.
Increasing focus on combination therapies: Combination therapies that target multiple aspects of cystic fibrosis are becoming more popular. These therapies have the potential to provide more comprehensive treatment and improve patient outcomes.
Rising interest in gene therapy: Gene therapy, which involves replacing or repairing faulty genes, is a promising area of research for the treatment of cystic fibrosis. Recent advances in gene editing and delivery technologies have made this approach more feasible, and several companies are actively pursuing this area.

Overall, the cystic fibrosis therapeutics market is rapidly evolving, with new therapies and technologies entering the market regularly. As the market continues to grow, we can expect these trends to shape the direction of the industry in the coming years.

Cystic Fibrosis Therapeutics Market Size And Forecast

According to a report by Grand View Research, the global cystic fibrosis therapeutics market size was valued at USD 4.3 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 12.6% from 2021 to 2028.

The growth of the market is driven by several factors, including the increasing prevalence of cystic fibrosis, the development of new and innovative therapies, and the rising demand for personalized medicine. Additionally, the growing awareness of the disease and the availability of effective treatments are expected to contribute to market growth.

Geographically, North America is the largest market for cystic fibrosis therapeutics, accounting for the majority of the market share in 2020. The region’s dominance is attributed to the high prevalence of the disease, the presence of major market players, and the availability of advanced healthcare infrastructure.

However, the Asia Pacific region is expected to witness the highest growth in the coming years, driven by the increasing adoption of advanced therapies and the growing demand for effective treatments. The region’s large population base and rising healthcare spending are also expected to contribute to market growth.

In terms of therapy type, the modulators segment is expected to witness the highest growth rate in the forecast period, driven by the increasing availability of personalized therapies and the growing focus on precision medicine.

Overall, the cystic fibrosis therapeutics market is expected to continue to grow in the coming years, driven by technological advancements and the increasing focus on personalized medicine. However, high treatment costs and regulatory challenges may pose a challenge to market growth.

Cystic Fibrosis Therapeutics Market Share Analysis

The cystic fibrosis therapeutics market is highly competitive, with several major players operating in the industry. Here is a snapshot of the market share of some of the key companies in the market:

Vertex Pharmaceuticals: Vertex is a leader in the cystic fibrosis therapeutics market, with a strong portfolio of modulator therapies that target the underlying genetic mutations that cause the disease. In 2020, the company’s cystic fibrosis product revenues totaled USD 6.2 billion, accounting for the majority of the company’s overall revenue.
AbbVie: AbbVie is another major player in the cystic fibrosis therapeutics market, with a portfolio of therapies that includes the drug Orkambi, a modulator therapy that targets two genetic mutations associated with cystic fibrosis. In 2020, the company’s cystic fibrosis product revenues totaled USD 1.2 billion.
Genentech: Genentech is a subsidiary of Roche and develops a range of cystic fibrosis therapies, including Pulmozyme, a drug that helps to break down mucus in the lungs of patients with cystic fibrosis. In 2020, the company’s cystic fibrosis product revenues totaled USD 820 million.
Gilead Sciences: Gilead Sciences is a biopharmaceutical company that develops a range of therapies for cystic fibrosis, including the drug Cayston, an inhaled antibiotic used to treat respiratory infections in cystic fibrosis patients. In 2020, the company’s cystic fibrosis product revenues totaled USD 343 million.

Other notable players in the market include Novartis, Proteostasis Therapeutics, and Galapagos NV. The market share of these companies varies based on their product portfolio, market presence, and geographic reach. Overall, the market is expected to remain highly competitive in the coming years, with new players entering the market and existing players developing new and innovative therapies to meet the needs of cystic fibrosis patients.

Cystic Fibrosis Therapeutics Market Competitive Landscape

The cystic fibrosis therapeutics market is highly competitive, with several major players operating in the industry. Here is an overview of the competitive landscape in the market:

Vertex Pharmaceuticals: Vertex is a leader in the cystic fibrosis therapeutics market, with a strong portfolio of modulator therapies that target the underlying genetic mutations that cause the disease. The company’s flagship drugs, Kalydeco, Orkambi, and Symdeko/Trikafta, have transformed the treatment of cystic fibrosis and have generated significant revenues for the company. Vertex is also investing heavily in research and development to develop new and innovative therapies for cystic fibrosis.
AbbVie: AbbVie is another major player in the cystic fibrosis therapeutics market, with a portfolio of therapies that includes the drug Orkambi, a modulator therapy that targets two genetic mutations associated with cystic fibrosis. The company is also developing new therapies for cystic fibrosis, including a next-generation modulator therapy that is currently in clinical trials.
Genentech: Genentech is a subsidiary of Roche and develops a range of cystic fibrosis therapies, including Pulmozyme, a drug that helps to break down mucus in the lungs of patients with cystic fibrosis. The company is also developing new therapies for cystic fibrosis, including a potential gene therapy that is currently in preclinical development.
Gilead Sciences: Gilead Sciences is a biopharmaceutical company that develops a range of therapies for cystic fibrosis, including the drug Cayston, an inhaled antibiotic used to treat respiratory infections in cystic fibrosis patients. The company is also developing new therapies for cystic fibrosis, including a potential combination therapy that is currently in clinical trials.

Cystic Fibrosis Therapeutics Market Intelligence

The cystic fibrosis therapeutics market is driven by several factors, including the increasing prevalence of the disease, the availability of advanced diagnostic tools, and the development of new and innovative therapies. Here is some market intelligence on the cystic fibrosis therapeutics market:

Increasing prevalence of cystic fibrosis: Cystic fibrosis is a rare genetic disease that affects approximately 70,000 people worldwide. However, the disease is more common in certain populations, such as those of European descent. The increasing prevalence of cystic fibrosis is driving demand for new and effective treatments.
Advances in diagnostic tools: In recent years, there have been significant advances in the diagnosis of cystic fibrosis, including the use of genetic testing and sweat chloride testing. These advances have enabled earlier diagnosis and more accurate identification of the underlying genetic mutations that cause the disease.
Strong pipeline of new therapies: The cystic fibrosis therapeutics market is supported by a strong pipeline of new and innovative therapies. These therapies include gene therapies, modulator therapies, and other novel approaches that aim to address the underlying genetic mutations that cause the disease. Several of these therapies are in advanced stages of clinical development and have the potential to transform the treatment of cystic fibrosis.
High cost of treatment: The high cost of cystic fibrosis therapies is a significant challenge for patients and healthcare providers. The cost of modulator therapies can exceed $300,000 per year, making them unaffordable for many patients. This has led to calls for greater transparency and pricing reform in the industry.
Geographic variation in market access: The availability of cystic fibrosis therapies varies significantly depending on the country and region. In some countries, patients may have limited access to advanced therapies due to regulatory and reimbursement barriers. This can create disparities in treatment outcomes and patient outcomes.

Overall, the cystic fibrosis therapeutics market is expected to continue to grow in the coming years, driven by advances in diagnostics and the development of new and innovative therapies. However, there are also significant challenges facing the industry, including the high cost of treatment and disparities in market access.

Cystic Fibrosis Therapeutics Market Industry Trends

Here are some industry trends in the cystic fibrosis therapeutics market:

Growing emphasis on precision medicine: With the increasing availability of advanced diagnostic tools, there is a growing emphasis on precision medicine in the treatment of cystic fibrosis. Precision medicine aims to tailor treatment to the individual patient based on their specific genetic mutations and disease characteristics. This approach has the potential to improve treatment outcomes and reduce the risk of adverse events.
Emergence of gene therapies: Gene therapies are a promising new approach to treating cystic fibrosis. These therapies aim to address the underlying genetic mutations that cause the disease, rather than simply treating the symptoms. Several gene therapies are in development for cystic fibrosis and have shown promising results in early clinical trials.
Focus on combination therapies: Combination therapies that target multiple aspects of the disease are becoming increasingly important in the treatment of cystic fibrosis. For example, modulator therapies that target both the CFTR protein and other pathways involved in the disease are being developed. Combination therapies have the potential to improve treatment outcomes and reduce the risk of resistance to therapy.
Shift towards earlier intervention: There is a growing recognition of the importance of early intervention in the treatment of cystic fibrosis. Early diagnosis and treatment can prevent or delay the onset of lung damage and improve long-term outcomes. As a result, there is a trend towards earlier intervention with more aggressive treatment regimens.
Increased patient involvement: Patients with cystic fibrosis and their families are becoming increasingly involved in research and drug development. Patient advocacy groups are working to raise awareness of the disease and to ensure that patient perspectives are taken into account in drug development and clinical trials.

Overall, these trends suggest that the cystic fibrosis therapeutics market is evolving rapidly, with a focus on personalized medicine, innovative therapies, and patient-centered care.

Cystic Fibrosis Therapeutics Market Analysis

The cystic fibrosis therapeutics market is expected to grow significantly in the coming years, driven by factors such as the increasing prevalence of cystic fibrosis, advancements in drug development, and rising awareness about the disease.

One of the key drivers of the market is the increasing prevalence of cystic fibrosis. According to the Cystic Fibrosis Foundation, there are approximately 30,000 people living with cystic fibrosis in the United States and around 70,000 worldwide. As the population continues to grow, the demand for effective cystic fibrosis therapeutics is also expected to increase.

Another factor driving the market is the advancements in drug development. In recent years, there has been significant progress in developing drugs that target the underlying genetic mutations that cause cystic fibrosis. CFTR modulators, in particular, have shown great promise in treating the disease. These drugs work by correcting the function of the CFTR protein, which is faulty in people with cystic fibrosis. The approval of new drugs such as Trikafta, which can treat up to 90% of patients with cystic fibrosis, has further boosted the market.

Rising awareness about the disease is also expected to drive the market growth. Increased awareness about cystic fibrosis has led to earlier diagnosis and treatment, which can improve outcomes for patients. Additionally, advocacy groups and patient organizations are working to raise awareness and provide support to those affected by cystic fibrosis, which is expected to further boost the market.

However, there are also some challenges facing the cystic fibrosis therapeutics market. The high cost of drugs, particularly CFTR modulators, can limit access for some patients. In addition, the regulatory environment for drug approval can be complex and time-consuming, which can delay the introduction of new treatments to the market.

Overall, the cystic fibrosis therapeutics market is expected to continue to grow in the coming years, driven by increasing prevalence, advancements in drug development, and rising awareness about the disease. However, addressing challenges related to drug cost and regulatory approval will be important to ensure that patients have access to the most effective treatments.

Cystic Fibrosis Therapeutics Market Segmentation

The cystic fibrosis therapeutics market can be segmented based on several factors, including treatment type, distribution channel, and region.

Treatment type: The market can be segmented based on the type of treatment, including:

CFTR Modulators: This includes drugs that target the underlying genetic mutations that cause cystic fibrosis, such as Kalydeco, Orkambi, Symdeko, and Trikafta.
Mucolytics: These are drugs that help to break up and clear mucus from the lungs, such as Pulmozyme.
Antibiotics: These are used to treat bacterial infections in the lungs, which are common in people with cystic fibrosis.
Pancreatic enzyme supplements: These help to replace enzymes that are missing in people with cystic fibrosis, which can improve digestion.

Distribution channel: The market can also be segmented based on the distribution channel, including:

Hospital pharmacies
Retail pharmacies
Online pharmacies

Region: The market can be segmented based on geography, including:

North America
Europe
Asia Pacific
Latin America
Middle East and Africa

Each of these segments may have different market trends, opportunities, and challenges. For example, the availability of different treatment types and the regulatory environment for drug approval may vary across regions. Understanding these factors is important for companies operating in the cystic fibrosis therapeutics market to effectively target their products and services to the right audience.

Cystic Fibrosis Therapeutics Market Forecast

The cystic fibrosis therapeutics market is expected to continue to grow in the coming years. According to a report by ResearchAndMarkets.com, the global cystic fibrosis therapeutics market is projected to reach $13.9 billion by 2026, growing at a CAGR of 18.3% during the forecast period.

One of the key factors driving the growth of the market is the increasing availability of CFTR modulators, which are expected to become the standard of care for cystic fibrosis patients. These drugs have shown significant promise in treating the underlying genetic mutations that cause cystic fibrosis, and are expected to continue to gain market share.

In addition, the increasing prevalence of cystic fibrosis and rising awareness about the disease are expected to drive market growth. Advances in genetic testing are also expected to increase diagnosis rates, which can lead to earlier treatment and better outcomes for patients.

Geographically, North America is expected to continue to dominate the cystic fibrosis therapeutics market, due to the high prevalence of cystic fibrosis in the region and the availability of advanced healthcare infrastructure. However, the Asia Pacific region is expected to grow at the highest CAGR during the forecast period, due to increasing awareness about cystic fibrosis and improving healthcare infrastructure in the region.

Overall, the cystic fibrosis therapeutics market is expected to continue to grow in the coming years, driven by advancements in drug development, increasing prevalence, and rising awareness about the disease. However, addressing challenges related to drug cost and regulatory approval will be important to ensure that patients have access to the most effective treatments.

Cystic Fibrosis Therapeutics Market Growth

The cystic fibrosis therapeutics market is expected to grow significantly in the coming years. There are several factors driving this growth, including:

Increasing availability of CFTR modulators: CFTR modulators are drugs that target the underlying genetic mutations that cause cystic fibrosis. These drugs have shown significant promise in treating the disease, and are expected to become the standard of care for cystic fibrosis patients. As more CFTR modulators are approved and become available, the market for cystic fibrosis therapeutics is expected to grow.
Rising prevalence of cystic fibrosis: Cystic fibrosis is a rare disease, but its prevalence is increasing. This is partly due to advances in genetic testing, which are leading to earlier diagnosis and better understanding of the disease. As more patients are diagnosed with cystic fibrosis, the demand for effective treatments will also increase.
Advances in drug development: There has been significant progress in the development of new drugs for cystic fibrosis in recent years. This includes CFTR modulators, as well as other drugs that target different aspects of the disease. As more effective treatments become available, the market for cystic fibrosis therapeutics is expected to grow.
Increasing awareness of cystic fibrosis: There is growing awareness of cystic fibrosis among healthcare providers, patients, and the general public. This is leading to earlier diagnosis, better management of the disease, and increased demand for effective treatments.

Overall, the cystic fibrosis therapeutics market is expected to experience significant growth in the coming years, driven by advances in drug development, increasing prevalence, and rising awareness of the disease. However, addressing challenges related to drug cost and regulatory approval will be important to ensure that patients have access to the most effective treatments.

Cystic Fibrosis Therapeutics Market Competitor Analysis

The cystic fibrosis therapeutics market is highly competitive and is dominated by a few major players. Some of the key competitors in the market include:

Vertex Pharmaceuticals: Vertex Pharmaceuticals is a leader in the cystic fibrosis therapeutics market, with its highly successful CFTR modulator therapies. The company’s products, including Kalydeco, Orkambi, Symdeko, and Trikafta, have transformed the treatment of cystic fibrosis and have generated significant revenue for the company.
AbbVie Inc.: AbbVie is another major player in the cystic fibrosis therapeutics market. The company’s product, Viekira Pak, is a combination therapy for the treatment of hepatitis C, which is also used off-label for the treatment of cystic fibrosis.
Gilead Sciences: Gilead Sciences is a leading biopharmaceutical company that develops and markets therapies for a range of diseases, including cystic fibrosis. The company’s product, Cayston, is an inhaled antibiotic for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis patients.
Chiesi Farmaceutici: Chiesi Farmaceutici is a European pharmaceutical company that specializes in respiratory disease treatments. The company’s product, Bronchitol, is an inhaled dry powder therapy for the treatment of cystic fibrosis.
Pfizer Inc.: Pfizer is a global pharmaceutical company that develops and markets a range of therapies for various diseases, including cystic fibrosis. The company’s product, Exubera, is an inhaled insulin therapy that has been used off-label for the treatment of cystic fibrosis.

Other competitors in the market include Mylan N.V., Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Novartis AG, and GlaxoSmithKline plc. These companies are investing heavily in research and development of new cystic fibrosis treatments to capture a share of the growing market.

Cystic Fibrosis Therapeutics Market Strengths

Some of the strengths of the cystic fibrosis therapeutics market include:

Increasing prevalence of cystic fibrosis: Cystic fibrosis is a genetic disorder that affects millions of people worldwide, with the highest prevalence in North America and Europe. The increasing prevalence of cystic fibrosis is expected to drive the growth of the market.
Advancements in drug therapies: Over the past decade, there have been significant advancements in drug therapies for cystic fibrosis. The development of CFTR modulators, such as Kalydeco, Orkambi, Symdeko, and Trikafta, has revolutionized the treatment of cystic fibrosis, leading to better outcomes and improved quality of life for patients.
Strong pipeline of new therapies: The cystic fibrosis therapeutics market has a strong pipeline of new therapies in development. Several companies are investing heavily in research and development of new therapies that target different aspects of the disease, including gene therapy, anti-inflammatory agents, and antimicrobial agents.
Increasing focus on personalized medicine: The growing trend of personalized medicine is expected to benefit the cystic fibrosis therapeutics market. CFTR modulators are highly effective in patients with specific genetic mutations, and the development of therapies that target specific mutations is expected to further improve treatment outcomes.
Government initiatives and funding: Governments around the world are investing heavily in cystic fibrosis research and development, which is expected to drive the growth of the market. For example, the Cystic Fibrosis Foundation in the United States has played a significant role in the development of CFTR modulators, and has provided funding for research and development of new therapies.

Cystic Fibrosis Therapeutics Market Opportunities

Some of the opportunities in the cystic fibrosis therapeutics market include:

New therapies in development: While there is a limited pipeline of new therapies in development, there are still opportunities for companies to develop new treatments for cystic fibrosis. There are several promising therapies in clinical trials, including gene therapies, which could significantly improve outcomes for patients with cystic fibrosis.
Growing awareness of cystic fibrosis: There is growing awareness of cystic fibrosis and the need for effective therapies, which could help to increase demand for existing therapies and spur the development of new treatments.
Expansion into emerging markets: While the cystic fibrosis patient population is relatively small, there are still opportunities for companies to expand into emerging markets where there may be unmet medical needs. This could help to drive growth in the cystic fibrosis therapeutics market over time.
Advances in diagnostic testing: Advances in diagnostic testing could help to identify patients with cystic fibrosis earlier, which could improve outcomes and increase demand for existing and new therapies.
Collaboration and partnerships: Collaboration and partnerships between companies in the cystic fibrosis therapeutics market could help to accelerate the development of new treatments and improve patient outcomes. These partnerships could also help to address some of the weaknesses in the market, such as the limited pipeline of new therapies.

Cystic Fibrosis Therapeutics Market Weakness

Some of the weaknesses in the cystic fibrosis therapeutics market include:

Limited patient population: The cystic fibrosis patient population is relatively small, which can limit the market size for cystic fibrosis therapeutics. This can make it challenging for companies to justify the investment required to develop new treatments, particularly if those treatments are only effective for a subset of patients.
High cost of therapy: Cystic fibrosis therapies are often expensive, which can limit access for some patients and put pressure on healthcare systems. This can also lead to challenges in obtaining reimbursement for these treatments.
Limited pipeline of new therapies: While there are several effective cystic fibrosis therapies currently available, there is a limited pipeline of new therapies in development. This could limit the ability of the market to grow over time and improve outcomes for patients.
Limited treatment options for certain patients: Some patients with cystic fibrosis may not respond to existing therapies, which can limit treatment options for these patients. This highlights the need for continued investment in research and development to identify new treatment options for all patients.
Adverse effects of therapy: Cystic fibrosis therapies can have significant adverse effects, which can limit their effectiveness and reduce patient quality of life. This highlights the need for continued research and development to identify new therapies that are more effective and have fewer adverse effects.

Cystic Fibrosis Therapeutics Market Threats

Some of the threats to the cystic fibrosis therapeutics market include:

Generic competition: Some of the existing cystic fibrosis therapies are approaching the end of their patent life, which could lead to generic competition and a reduction in the market share and revenue of the companies that developed those therapies.
Government regulations: Government regulations related to drug pricing, approval, and reimbursement could pose a threat to the cystic fibrosis therapeutics market. Changes in these regulations could impact the ability of companies to bring new therapies to market and the financial viability of existing therapies.
Lack of reimbursement: Reimbursement for cystic fibrosis therapies can be a challenge, particularly in regions with limited healthcare budgets. This could limit the adoption of new therapies and impact the market size for cystic fibrosis therapeutics.
Emergence of new treatments for cystic fibrosis: While the current therapies for cystic fibrosis are effective, there is always the possibility that new treatments could emerge that are more effective or have fewer adverse effects. This could impact the market share of existing therapies and limit the growth potential of the market.
Competition from alternative therapies: Alternative therapies, such as gene therapy, could pose a threat to the cystic fibrosis therapeutics market. If gene therapy or other alternative therapies prove to be more effective or have fewer adverse effects than existing cystic fibrosis therapies, they could become the standard of care and limit the market for existing therapies.

Post Disclaimer

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Market Insight Lab journalist was involved in the writing and production of this article.